Scope, Claims, and U.S. Patent Landscape for US Drug Patent 10,543,219
US Drug Patent 10,543,219 is a method-of-treatment patent tied to oral testosterone undecanoate dosing at ~475 mg/day with food, using a specific oral excipient system. The claims are drafted to narrow around (i) dose, (ii) oral formulation composition ranges and exemplified ratios, and (iii) administration frequency plus testosterone pharmacodynamic targets, with an explicit focus on primary hypogonadism in dependent claim coverage.
What exactly does the patent claim (and what does it not)?
The operative claim concept is: treat testosterone deficiency or its symptoms in a male by daily administering about 475 mg testosterone undecanoate, where the undecanoate is delivered in an oral pharmaceutical composition with food containing a defined lipid/surfactant/oil blend, including oleic acid, polyoxyethylene (40) hydrogenated castor oil, and a borage seed oil/peppermint oil mixture.
What it does not claim:
- It does not claim an injectable regimen.
- It does not broadly claim “oral testosterone undecanoate” with generic self-emulsifying systems.
- It does not claim all dosing amounts; the anchor is about 475 mg/day.
- It does not claim alternate excipient systems unless they fall within the recited composition constraints (or equivalent language that captures them, if any, is not shown in the provided claim text).
Claim-by-Claim Scope Map (1 to 12)
Independent claim 1: baseline scope
Claim 1 is the core method claim. It requires all of the following:
-
Indication/population
- Male with testosterone deficiency or its symptoms.
-
Dose
- Daily administering about 475 mg testosterone undecanoate.
-
Route + administration conditions
- Testosterone undecanoate administered in an oral pharmaceutical composition with food.
-
Composition requirements (by weight of the oral composition)
- 18-22% solubilized testosterone undecanoate
- 50-55% oleic acid
- 15-17% polyoxyethylene (40) hydrogenated castor oil
- 10-15% mixture of borage seed oil and peppermint oil
Scope implications
- The formulation is not just “lipid-based.” It is constrained to a 4-component excipient architecture with tight ranges.
- “Solubilized testosterone undecanoate” is a qualifier that can matter for infringement proof because it ties the drug’s physical presentation (solubilized form) to the claim.
Dependent claim 2: narrows to a mid-point strength
Claim 2 narrows claim 1 by requiring:
- ~20% by weight testosterone undecanoate (within the claim 1 range).
Scope implications
- This claim is a “narrower lane” within claim 1. A product at 19.9% may fall under claim 1 but not claim 2, and vice versa depending on exact formulation.
Dependent claim 3: locks an example blend
Claim 3 requires an exact composition (as weighted percentages):
- 19.8% solubilized testosterone undecanoate
- 51.6% oleic acid
- 16.1% polyoxyethylene (40) hydrogenated castor oil
- 10% borage seed oil
- 2.5% peppermint oil
Scope implications
- This is a direct numerical lock. Any deviation in any component can help design-around unless doctrine of equivalents is argued in litigation.
Dependent claim 4: adds antioxidants
Claim 4: composition further comprises one or more antioxidants.
Scope implications
- Antioxidant presence broadens the covered subject matter only if the underlying 4-component blend is already met (since it is dependent on claim 1).
Dependent claim 5: dosage form as capsule
Claim 5: oral composition is in capsule form.
Scope implications
- This is a narrowing constraint. If a competitor sells tablets, softgels with different structural packaging, or multipart forms, claim 5 may not apply even if composition and dosing conditions do.
Dependent claim 6: pharmacodynamic target
Claim 6: administration results in serum testosterone “Cave” range of 300-1100 ng/dL.
Scope implications
- “Cave” implies an average serum exposure metric (commonly trough/averaged exposure depending on the claim’s definition in the patent spec). Infringement typically requires evidence from clinical or modeled results for a treated cohort.
Dependent claims 7 and 8: dosing frequency
- Claim 7: administered once daily
- Claim 8: administered twice daily
Scope implications
- Claim 1 does not explicitly fix once vs twice daily; it requires daily administering about 475 mg. Claim 7 and 8 specify the frequency and can split enforcement strategy.
Dependent claim 9: Cave target tied to twice-daily dosing
Claim 9: claim 8 plus serum testosterone Cave 300-1100 ng/dL.
Dependent claim 10: indication narrows to primary hypogonadism
Claim 10: male has primary hypogonadism.
Scope implications
- This limits claim 10 enforcement. If an accused product is used for secondary hypogonadism, claim 10 may not attach, but claim 1 still covers testosterone deficiency generally in a male unless secondary hypogonadism is argued as outside “testosterone deficiency or its symptoms” as construed in the patent.
Dependent claim 11: primary hypogonadism + exact composition + twice daily
Claim 11 is method for primary hypogonadism with:
- Daily administering about 475 mg testosterone undecanoate
- Oral composition
- Twice daily with food
- Exact composition:
- 19.8% solubilized testosterone undecanoate
- 51.6% oleic acid
- 16.1% polyoxyethylene (40) hydrogenated castor oil
- 10% borage seed oil
- 2.5% peppermint oil
Dependent claim 12: primary hypogonadism + twice daily + Cave target
Claim 12: claim 11 plus serum testosterone Cave 300-1100 ng/dL.
What is the “engine” of infringement risk here?
For a competitor to infringe any claim (as provided), it must meet all required elements for that claim. Practically, the high-friction elements are:
- Dose anchor: “about 475 mg” testosterone undecanoate daily
- Oral + with food condition
- Composition architecture and ranges (claim 1) or exact recipe (claims 3, 11)
- Frequency (once daily vs twice daily)
- Testosterone exposure target (claims 6, 9, 12)
- Patient subtype (primary hypogonadism) for claims 10, 11, 12
- Capsule form for claim 5
How the claim set creates layered coverage (enforcement pattern)
The claim structure provides two enforcement pathways:
A. Composition-layer claims (hard physical constraints)
- Claim 1: ranges for all four excipient components + solubilized undecanoate
- Claim 3 / 11: exact numerical blend
If a competitor uses an alternative formulation outside the ranges, it can break claim 1 and avoid claims 2, 3, 11. That said, partial overlap can still create exposure if the product is within the specified bands.
B. Regimen-layer claims (use instructions + physiologic outcomes)
- Frequency: claims 7 and 8
- Serum testosterone Cave: claims 6, 9, 12
- Primary hypogonadism: claims 10, 11, 12
If formulation and dose are close but the product is positioned for a different patient subtype, or the label uses a different dosing schedule, enforcement can shift to the broader claim 1 coverage if the “testosterone deficiency” population is still implicated.
Key design-arounds implied by the claim text
Based on the constraints shown, the main off-ramps are:
-
Dose not “about 475 mg” daily
- If a product is dosed materially below or above 475 mg/day, it can try to avoid claim 1. Exact “about” boundaries are fact-intensive, but the claims emphasize the anchor dose.
-
Change the excipient system
- Moving outside:
- 18-22% solubilized testosterone undecanoate
- 50-55% oleic acid
- 15-17% polyoxyethylene (40) hydrogenated castor oil
- 10-15% borage/peppermint mixture (with specific borage vs peppermint proportions for claim 3)
-
Change the dosing frequency
- If a product is only once daily and not twice daily, it can avoid claims explicitly requiring twice-daily (8, 9, 11, 12).
-
Avoid primary hypogonadism positioning
- Labeling, study design, and clinical indication claims can reduce applicability of dependent claims 10, 11, 12.
-
Avoid capsule dosage form
- If it is not a capsule, claim 5 may not apply.
U.S. Patent Landscape: how US10,543,219 likely sits in the broader portfolio
What kind of patent is this within US drug patent ecosystems?
This patent is a use method for testosterone replacement with an oral formulation + excipient composition. In the U.S. drug patent landscape, such patents typically interact with:
- Orange Book-listed New Drug Application (NDA) patents covering formulation/excipients and use methods
- Carve-outs for label instructions (timing, food effects, dosing schedule)
- Paragraph IV / litigation strategy in generic or 505(b)(2) routes that attempt to “design around” by changing formulation and/or dosing language
However, the provided prompt contains only the claim text; it does not include:
- the patent’s assignee,
- the related NDA/Orange Book listing,
- the reference product name,
- prosecution history,
- specification definitions of “Cave,” “solubilized,” or “mixture,”
- family members and continuations.
Given those missing datapoints, a complete, accurate landscape mapping (e.g., which patents are blocking, which are expiring, which are co-pending, which families cite US10,543,219) cannot be constructed from the claim text alone.
Therefore, the scope below stays strictly within the claim-driven landscape that can be derived from the text: how competitors would evaluate exposure and how claim dependencies drive freedom-to-operate decisions.
Practical Freedom-to-Operate Lens for this claim set
1) Formulation match test
A FTO review should check whether a candidate oral product:
- uses testosterone undecanoate delivered as solubilized
- falls within:
- 18-22% testosterone undecanoate (claim 1), or
- 19.8% (claims 2, 3, 11, 12), and
- uses oleic acid at 50-55% (claim 1) or 51.6% (claim 3/11/12)
- uses polyoxyethylene (40) hydrogenated castor oil at 15-17% (claim 1) or 16.1% (claim 3/11/12)
- uses borage seed oil + peppermint oil totaling 10-15% (claim 1), or specifically:
- 10% borage seed oil
- 2.5% peppermint oil (claim 3/11/12)
2) Regimen match test
Next check whether the label or dosing regimen:
- is with food
- gives daily ~475 mg
- uses once daily (claim 7) or twice daily (claim 8, 11)
- targets patients described as primary hypogonadism (claims 10-12)
3) Outcome test
For infringement theories that rely on physiologic targets:
- validate whether serum testosterone “Cave” is reported in the 300-1100 ng/dL window
- align whether the measurement corresponds to the same sampling basis used in the patent (the claim text says “Cave” but does not define it)
Key Takeaways
- US10,543,219 covers a method for treating male testosterone deficiency with oral testosterone undecanoate at about 475 mg/day administered with food in a tightly specified lipid/surfactant/oil formulation.
- The enforceable physical constraints are the excipient composition ranges in claim 1 and the exact blend in claims 3 and 11.
- Dependent claims add tripwires: once vs twice daily, primary hypogonadism, capsule form, and serum testosterone “Cave” 300-1100 ng/dL.
- The most direct design-arounds are changing dose, altering the excipient composition outside the specified ranges/percentages, and avoiding the twice-daily or primary hypogonadism positioning tied to dependent claims.
FAQs
1) What must an accused oral product match to infringe claim 1?
It must treat male testosterone deficiency by daily administering about 475 mg testosterone undecanoate, as an oral composition with food containing 18-22% solubilized testosterone undecanoate, 50-55% oleic acid, 15-17% polyoxyethylene (40) hydrogenated castor oil, and 10-15% borage seed oil plus peppermint oil mixture.
2) How does claim 3 differ from claim 1?
Claim 3 replaces the ranges with an exact recipe: 19.8% testosterone undecanoate, 51.6% oleic acid, 16.1% polyoxyethylene (40) hydrogenated castor oil, 10% borage seed oil, and 2.5% peppermint oil.
3) Do the serum testosterone targets apply to all claims?
No. The 300-1100 ng/dL “Cave” requirement appears in claims 6, 9, and 12, not in claim 1.
4) Can a product avoid infringement by changing from twice daily to once daily?
It can potentially avoid the dependent claims requiring twice daily (claims 8, 9, 11, 12). Claim 1 still remains broader because it requires only daily administration.
5) Does “capsule” matter?
Only for claim 5. If a product uses another oral dosage form while meeting the composition and regimen elements, claim 5 would not attach.
References
[1] U.S. Patent 10,543,219. Claims 1-12 (provided in prompt).
